Stifel reiterates Hold on ResMed stock amid market share concerns

Stifel maintained a Hold rating and $235 price target on ResMed, citing potential U.S. device-share erosion from 91% in 2026 to 87% next year, or 75% if Philips reenters the market; these risks are not reflected in Street estimates. The firm sees a favorable near-term setup because Philips' return is not expected imminently and fiscal Q1 2027 expectations appear modest, while GLP-1 survey feedback was supportive for CPAP demand. ResMed’s fiscal Q4 non-GAAP EPS of $2.95 beat the $2.89 consensus, though $1.46B revenue narrowly missed the $1.47B estimate; analysts remain divided, with recent bullish target increases to $262-$267 alongside neutral views.

Analysis

The investable issue is not near-term CPAP demand but the durability of RMD's exceptional U.S. device share and the operating leverage embedded in it. A credible PHG reentry would shift competition from supply-constrained replacement demand toward price, channel rebates, and DME contracting; a mid-teens share loss could therefore create more earnings downside than the associated revenue loss suggests. The Street appears positioned for continued mix and scale benefits, so fiscal-2028 deceleration would likely be expressed through multiple compression before consensus materially cuts estimates.

Near term (next 1-3 months), RMD has a favorable asymmetry if quarterly device volumes, resupply growth, and gross margin validate that competitive entry remains delayed. GLP-1 adoption is not necessarily cannibalistic: treated apnea patients may remain in therapy even after weight loss, while diagnosis, adherence monitoring, and higher-risk comorbidity screening can support the installed base. The key missing diligence is whether prospective competitor devices have sufficient regulatory clearance, manufacturing capacity, and DME/channel acceptance to convert a theoretical launch into meaningful share capture.

Contrarian view: PHG's return may be a slower and less economically rational threat than the bear case assumes, given the reputational, remediation, and channel-requalification burden after its recall history. Conversely, RMD is not a clean defensive healthcare long if a weakening labor backdrop broadens into lower insurance coverage or softer new-patient flow; monitor U.S. sleep-test referrals and DME order growth rather than headline GLP-1 prescription trends. APP, SMCI, and SF have no demonstrated transmission mechanism from this setup and should be excluded from trade construction.

Key Decisions for Investors

• Maintain or initiate a modest long RMD only on evidence of sustained device-volume growth and stable gross margin in the next earnings release; target a 6-12 month rerating toward the bullish analyst price range, with thesis invalidation if management guides to material fiscal-2028 growth deceleration or reports U.S. share erosion ahead of a competitor launch.
• Use PHG as the competitive-risk hedge rather than an outright short RMD: structure a 6-9 month long RMD / long PHG optionality position only after confirming PHG regulatory and commercial launch milestones. This limits exposure to a delayed-entry outcome while retaining upside if RMD's share moat holds.
• Do not chase RMD merely on valuation screens or the recent earnings beat. Set an alert for a confirmed PHG U.S. sleep-device reentry, DME contract wins, or RMD U.S. share below the high-80s; any of these would warrant reassessing RMD earnings estimates and reducing long exposure before consensus revisions.
• Monitor CPAP refill/resupply trends, sleep-lab referral volumes, and RMD gross margin over the next two quarters. Stable recurring-revenue behavior alongside delayed competitor commercialization supports the long; declining new setups plus rebate-driven margin pressure would make the risk/reward unattractive.